Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1-3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial

Blood (2024) 144 (Supplement 1): 1032.

https://doi.org/10.1182/blood-2024-201533

Published: 2024

Journal Articles

Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial

Blood (2024) 144 (Supplement 1): 2002.

https://doi.org/10.1182/blood-2024-209232

Published: 2024

Journal Articles

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Isatuximab, Carfilzomib and Dexamethasone in the Treatment of Patients with Lenalidomide-Refractory Multiple Myeloma with 1-3 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Blood (2024) 144 (Supplement 1): 7088.

https://doi.org/10.1182/blood-2024-205189

Published: 2024

Journal Articles

Prospective Feasibility Trial of Pharmacokinetic Directed Melphalan for Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation

Charlotte FM Hughes, Andrew Lin, Maria Bromberg, Sean M. Devlin, Amethyst Saldia, Danielle E Engstler, Danielle M Hanley, Yetunde Aremu, Martin Donach, Elizabeth Hoover, Oscar B Lahoud, Arnab Ghosh, Moneeza Walji, Miguel-Angel Perales, Michael Scordo, Sergio A. Giralt, Gunjan L. Shah, Parastoo B Dahi

Blood (2024) 144 (Supplement 1): 6492.

https://doi.org/10.1182/blood-2024-208310

Published: 2024

Journal Articles

Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial

Blood (2018) 132 (Supplement 1): 959.

https://doi.org/10.1182/blood-2018-99-119717

Published: 2018

Journal Articles

Development and Evaluation of a Human Single Chain Variable Fragment (scFv) Derived Bcma Targeted CAR T Cell Vector Leads to a High Objective Response Rate in Patients with Advanced MM

Blood (2017) 130 (Supplement 1): 742.

https://doi.org/10.1182/blood.V130.Suppl_1.742.742

Published: 2017

Journal Articles

TP53 Mutations in AML Predict Adverse Outcome in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant

Bartlomiej M Getta, MBBS, Arnab Ghosh, MD PhD, Catherine C. Coombs, MD, Sean Devlin, PhD, Maria Arcila, MD, Abhinita Mohanty, Ross L. Levine, MD, Martin S. Tallman, MD, Ann A. Jakubowski, MD PhD, Sergio A. Giralt, MD, Alan M Hanash, MD PhD

Blood (2016) 128 (22): 3481.

https://doi.org/10.1182/blood.V128.22.3481.3481

Published: 2016

Journal Articles

Murine Donor 1928z CAR T Cells Exert Potent Graft-Versus-Lymphoma Activity without Graft-Versus-Host-Disease

Melody Smith, MD, Arnab Ghosh, MD PhD, Scott James, MD PhD, Marco L Davila, MDPhD, Enrico Velardi, PhD, Kimon V. Argyropoulos, MD, Gertrude Gunset, Andrea Schietinger, PhD, Michel W. Sadelain, MD PhD, Marcel van den Brink, MD PhD

Blood (2016) 128 (22): 653.

https://doi.org/10.1182/blood.V128.22.653.653

Published: 2016

Journal Articles

Flow Cytometry Based Detection of MRD in Bone Marrow of Patients with Multiple Myeloma: A Comparison Between Fluorescent-Based Cytometry Versus Cytof

Arnab Ghosh, MD PhD, Nicole Carreau, MD, Alessandra Moscatello, Adeeb Rahman, PhD, Jingjing Qi, Seunghee Kim-Schulze, PhD, Shyamala C. Navada, MD, Ajai Chari, MD, Hearn Jay Cho, MD PhD, Sundar Jagannath, MD, Samir Parekh, MD

Blood (2015) 126 (23): 4195.

https://doi.org/10.1182/blood.V126.23.4195.4195

Published: 2015

Journal Articles

CD19-Targeted Donor T Cells Exert Potent Graft Versus Lymphoma Activity and Attenuated Gvhd

Arnab Ghosh, MD, PhD, Marco L. Davila, MD, PhD, Lauren F. Young, BS, Christopher Kloss, BS, Gertrude Gunset, BS, Odette M. Smith, BA, Mallory L. West, BS, Natalie V. Singer, BS, Amanda M. Holland, BS, Robert R. Jenq, MD, Alan M. Hanash, MD, PhD, Jarrod A. Dudakov, PhD, Enrico Velardi, PhD, Yusuke Shono, MD, PhD, Michel Sadelain, MD, PhD, Marcel R.M. van den Brink, MD, PhD

Blood (2012) 120 (21): 451.

https://doi.org/10.1182/blood.V120.21.451.451

Published: 2012

Journal Articles

Over-Expression of TRAIL on Donor T Cells Enhances GVT and Suppresses Gvhd Via Elimination of Alloreactive T Cells and Host APC

Arnab Ghosh, MD, PhD, Yildirim Dogan, PhD, Amanda M. Holland, BS, Odette M Smith, BA, Lauren F. Young, BS, Mallory L West, BS, Natalie V Singer, BS, Robert R Jenq, MD, Il-Kang Na, MD/PhD, Olaf Penack, MD/PhD, Alan M Hanash, MD, PhD, Martin G. Sauer, MD, Michel Sadelain, MD, PhD, Marcel R.M. van den Brink, MD, PhD

Blood (2011) 118 (21): 817.

https://doi.org/10.1182/blood.V118.21.817.817

Published: 2011

Journal Articles

Genetic Engineering of Donor T Cells for BMT Immunotherapy: Expression of TRAIL and PLZF Selectively Enhances GVT and Abrogates Gvhd

Arnab Ghosh, MD, PhD, Amanda M. Holland, BS, Yildirim Dogan, PhD, Nury Yim, BS, Uttam K. Rao, BA, Lauren F. Young, BS, Odette M. Smith, BA, Robert Jenq, MD, Il-Kang Na, MD/PhD, Jennifer Tsai, MD, Olaf Penack, MD/PhD, Alan M. Hanash, MD, PhD, Martin G. Sauer, MD, Derek Sant'Angelo, PhD, Michel Sadelain, MD, PhD, Marcel R.M. van den Brink, MD, PhD

Blood (2010) 116 (21): 730.

https://doi.org/10.1182/blood.V116.21.730.730

Published: 2010

Journal Articles

Concurrent visualization of trafficking, expansion, and activation of T lymphocytes and T-cell precursors in vivo

Il-Kang Na, John C. Markley, Jennifer J. Tsai, Nury L. Yim, Bradley J. Beattie, Alexander D. Klose, Amanda M. Holland, Arnab Ghosh, Uttam K. Rao, Matthias T. Stephan, Inna Serganova, Elmer B. Santos, Renier J. Brentjens, Ronald G. Blasberg, Michel Sadelain, Marcel R. M. van den Brink

Blood (2010) 116 (11): e18–e25.

https://doi.org/10.1182/blood-2009-12-259432

Published: 2010

Includes: Supplemental data

Journal Articles

NOD2 Regulates Hematopoietic Cell Function During Graft-Versus-Host Disease.

Olaf Penack, Odette M. Smith, Nury Yim, Uttam Rao, Arnab Ghosh, George F Murphy, Amanda M. Holland, Robert R. Jenq, MD, Sydney X Lu, Il-Kang Na, MD, Marcel R.M. van den Brink, MD, PhD

Blood (2009) 114 (22): 2453.

https://doi.org/10.1182/blood.V114.22.2453.2453

Published: 2009

Journal Articles

TRAIL/ DR5 Interactions Are Important for Thymic Damage After Allogeneic Bone Marrow Transplantation.

Blood (2009) 114 (22): 234.

https://doi.org/10.1182/blood.V114.22.234.234

Published: 2009

Journal Articles

Concurrent Visualization of Trafficking and NFAT Signalling in Primary T Lymphocytes and T Cell Precursors In Vivo.

Il-Kang Na, MD, John Markley, MD, PhD, Jennifer Tsai, MD, Nury L. Yim, Bradley J. Beattie, Alexander D. Klose, PhD, Amanda M. Holland, Arnab Ghosh, MD, PhD, Uttam K. Rao, Matthias Stephan, MD, PhD, Inna Serganova, PhD, Renier J. Brentjens, MD, PhD, Ron R.G. Blasberg, MD, Michel W Sadelain, MD, PhD, Marcel R.M. van den Brink, MD, PhD

Blood (2009) 114 (22): 914.

https://doi.org/10.1182/blood.V114.22.914.914

Published: 2009

Journal Articles

Donor T cells primed on leukemia lysate-pulsed recipient APCs mediate strong graft-versus-leukemia effects across MHC barriers in full chimeras

Arnab Ghosh, Wolfgang Koestner, Martin Hapke, Verena Schlaphoff, Florian Länger, Rolf Baumann, Christian Koenecke, Markus Cornberg, Karl Welte, Bruce R. Blazar, Martin G. Sauer

Blood (2009) 113 (18): 4440–4448.

https://doi.org/10.1182/blood-2008-09-181677

Published: 2009

Journal Articles

The T Cell Cytolytic Molecules Fas Ligand and TRAIL, the Trafficking Molecules CCR9, β7 Integrin and PSGL-1, and the Immune Modulating Molecules OX40, CEACAM1, and CTLA4 Are Required for Thymic Graft-Versus-Host Disease

Blood (2008) 112 (11): 65.

https://doi.org/10.1182/blood.V112.11.65.65

Published: 2008

Journal Articles

Depletion of Vascular Endothelial Progenitor Cells Inhibits Inflammation

Olaf Penack, Erik Henke, David Suh, Christopher King, Marsinay O Smith, Il-Kang Na, MD, Amanda Holland, Arnab Ghosh, Sydney X Lu, Robert Jenq, Chen Liu, George F Murphy, Theresa Lu, Chad May, David A. Scheinberg, MD, PhD, Ding Cheng Gao, Vivek Mittal, Robert Benezra, Marcel Van Den Brink, MD, PhD

Blood (2008) 112 (11): 694.

https://doi.org/10.1182/blood.V112.11.694.694

Published: 2008

Journal Articles

Ex Vivo Generated Cytotoxic T Cells (CTL) for Adoptive Immunotherapy across MHC Barriers Retain Anti-Leukemic Capacity (GVL) without Eliciting Graft Versus Host Disease (GVHD): Crucial Role of Recipient-Derived Antigen Presenting Cells (APC).

Arnab Ghosh, Martin Hapke, Florian Laenger, MD, Ralf Baumann, PhD, Christian Koenecke, MD, Karl Welte, MD, Martin Sauer, MD

Blood (2006) 108 (11): 3168.

https://doi.org/10.1182/blood.V108.11.3168.3168

Published: 2006

NARROW

Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1-3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial

Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Isatuximab, Carfilzomib and Dexamethasone in the Treatment of Patients with Lenalidomide-Refractory Multiple Myeloma with 1-3 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Prospective Feasibility Trial of Pharmacokinetic Directed Melphalan for Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation

Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial

Development and Evaluation of a Human Single Chain Variable Fragment (scFv) Derived Bcma Targeted CAR T Cell Vector Leads to a High Objective Response Rate in Patients with Advanced MM

TP53 Mutations in AML Predict Adverse Outcome in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant

Murine Donor 1928z CAR T Cells Exert Potent Graft-Versus-Lymphoma Activity without Graft-Versus-Host-Disease

Flow Cytometry Based Detection of MRD in Bone Marrow of Patients with Multiple Myeloma: A Comparison Between Fluorescent-Based Cytometry Versus Cytof

CD19-Targeted Donor T Cells Exert Potent Graft Versus Lymphoma Activity and Attenuated Gvhd

Over-Expression of TRAIL on Donor T Cells Enhances GVT and Suppresses Gvhd Via Elimination of Alloreactive T Cells and Host APC

Genetic Engineering of Donor T Cells for BMT Immunotherapy: Expression of TRAIL and PLZF Selectively Enhances GVT and Abrogates Gvhd

Concurrent visualization of trafficking, expansion, and activation of T lymphocytes and T-cell precursors in vivo

NOD2 Regulates Hematopoietic Cell Function During Graft-Versus-Host Disease.

TRAIL/ DR5 Interactions Are Important for Thymic Damage After Allogeneic Bone Marrow Transplantation.

Concurrent Visualization of Trafficking and NFAT Signalling in Primary T Lymphocytes and T Cell Precursors In Vivo.

Donor T cells primed on leukemia lysate-pulsed recipient APCs mediate strong graft-versus-leukemia effects across MHC barriers in full chimeras

The T Cell Cytolytic Molecules Fas Ligand and TRAIL, the Trafficking Molecules CCR9, β7 Integrin and PSGL-1, and the Immune Modulating Molecules OX40, CEACAM1, and CTLA4 Are Required for Thymic Graft-Versus-Host Disease

Depletion of Vascular Endothelial Progenitor Cells Inhibits Inflammation

Ex Vivo Generated Cytotoxic T Cells (CTL) for Adoptive Immunotherapy across MHC Barriers Retain Anti-Leukemic Capacity (GVL) without Eliciting Graft Versus Host Disease (GVHD): Crucial Role of Recipient-Derived Antigen Presenting Cells (APC).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only